Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
11
×
life sciences
medicare
11
×
national blog main
11
×
boston blog main
san francisco blog main
san francisco top stories
boston top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
wisconsin blog main
wisconsin top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
eli lilly
clinical trials
cancer
scott gottlieb
startups
amgen
biogen
bristol-myers squibb
cancer immunotherapy
celgene
deals
What
bio
roundup
drug
industry
ipo
price
week
alzheimer’s
annual
biotech
cancer
companies
days
drugs
fallout
hasn’t
life
new
notes
prices
research
science
thanks
trump
administration
adversity
afternoon
airport
allogene
angry
anti
anticipated
apocalypse
appetite
arena’s
arrival
assessed
attention
awaited
beats
Language
unset
Current search:
medicare
×
" national blog main "
×
fda
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com
6 years ago
Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up